Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts

Bone

Volumn 44, Issue 2, 2009, Pages 275-286

  Jilka, Robert L ^a   O'Brien, Charles A ^a   Ali, A Afshan ^a   Roberson, Paula K ^a   Weinstein, Robert S ^a   Manolagas, Stavros C ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Apoptosis; Bone formation; Cancellous bone; Osteoblasts; Periosteal bone; PTH

Indexed keywords

BROXURIDINE; GANCICLOVIR; PARATHYROID HORMONE; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCELLOUS BONE; CELL PROLIFERATION; LUMBAR VERTEBRA; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PERIOSTEUM; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; CELL COUNT; COLLAGEN TYPE I; DNA REPLICATION; FEMALE; GANCICLOVIR; MALE; MICE; MITOSIS; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOGENESIS; PARATHYROID HORMONE; PERIOSTEUM; STEM CELLS; THYMIDINE KINASE; TIME FACTORS;

EID: 58349093551     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.10.037     Document Type: Article

References (45)

1. Compston J.E. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 40 (2007) 1447-1452
2. Hodsman A.B., Bauer D.C., Dempster D., Dian L., Hanley D.A., Harris S.T., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr. Rev. 26 (2005) 688-703
3. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
4. Iida-Klein A., Lu S.S., Cosman F., Lindsay R., and Dempster D.W. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. Bone 40 (2007) 391-398
5. Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., and Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104 (1999) 439-446
6. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone Miner. Res. 16 (2001) 1846-1853
7. Hirano T., Burr D.B., Turner C.H., Sato M., Cain R.L., and Hock J.M. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J. Bone Miner. Res. 14 (1999) 536-545
8. Lindsay R., Zhou H., Cosman F., Nieves J., Dempster D.W., and Hodsman A.B. Effects of a one-month treatment with parathyroid hormone (1-34) on bone formation on cancellous, endocortical and periosteal surfaces of the human ilium. J. Bone Miner. Res. 22 (2007) 495-502
9. Rehman Q., Lang T.F., Arnaud C.D., Modin G.W., and Lane N.E. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos. Int. 14 (2003) 77-81
10. Aubin J.E., and Triffitt J.T. Mesenchymal stem cells and osteoblast differentiation. In: Bilezikian J.P., Raisz L.G., and Rodan G. (Eds). Principles of bone biology. 2nd Edition (2002), Academic Press, San Diego 59-81
11. Owen M. Cellular dynamics of bone. In: Bourne G.H. (Ed). Volume III. Development and growth (1971), Academic Press, New York, NY 271-298
12. Kember N.F. Cell population kinetics of bone growth: the first ten years of autoradiographic studies with tritiated thymidine. Clin. Orthop. 76 (1971) 213-230
13. Rice D.P., Kim H.J., and Thesleff I. Apoptosis in murine calvarial bone and suture development. Eur. J. Oral. Sci. 107 (1999) 265-275
14. Li G., Dickson G.R., Marsh D.R., and Simpson H. Rapid new bone tissue remodeling during distraction osteogenesis is associated with apoptosis. J. Orthop. Res. 21 (2003) 28-35
15. Parfitt A.M. Bone-forming cells in clinical conditions. In: Hall B.K. (Ed). Bone. Volume 1. The osteoblast and osteocyte (1990), Telford Press and CRC Press, Boca Raton, FL 351-429
16. Jilka R.L., Weinstein R.S., Bellido T., Parfitt A.M., and Manolagas S.C. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J. Bone Miner. Res. 13 (1998) 793-802
17. Jilka R.L., Bellido T., Almeida M., Plotkin L.I., O'Brien C.A., Weinstein R.S., et al. Apoptosis in bone cells. In: Bilezikian J.P., Raisz L.G., and Martin T.J. (Eds). Principles of bone biology. 3rd Edition (2008), Academic Press, San Diego 237-261
18. Jilka R.L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40 (2007) 1434-1446
19. Miao D., He B., Jiang Y., Kobayashi T., Soroceanu M.A., Zhao J., et al. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J. Clin. Invest. 115 (2005) 2402-2411
20. Bellido T., Ali A.A., Plotkin L.I., Fu Q., Gubrij I., Roberson P.K., et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts: a putative explanation for why intermittent administration is needed for bone anabolism. J. Biol. Chem. 278 (2003) 50259-50272
21. Jilka R.L., Weinstein R.S., Parfitt A.M., and Manolagas S.C. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J. Bone Miner. Res. 22 (2007) 1492-1501
22. Tonna E.A., and Cronkite E.P. Skeletal cell labeling following continuous infusion with tritiated thymidine. Lab. Invest. 19 (1968) 510-515
23. Allen M.R., Hock J.M., and Burr D.B. Periosteum: biology, regulation, and response to osteoporosis therapies. Bone 35 (2004) 1003-1012
24. Kalajzic I., Kalajzic Z., Kaliterna M., Gronowicz G., Clark S.H., Lichtler A.C., et al. Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage. J. Bone Miner. Res. 17 (2002) 15-25
25. al Shawi R., Burke J., Jones C.T., Simons J.P., and Bishop J.O. A Mup promoter-thymidine kinase reporter gene shows relaxed tissue-specific expression and confers male sterility upon transgenic mice. Mol. Cell. Biol. 8 (1988) 4821-4828
26. Weinstein R.S., Jilka R.L., Parfitt A.M., and Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102 (1998) 274-282
27. Jilka R.L., Weinstein R.S., Takahashi K., Parfitt A.M., and Manolagas S.C. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J. Clin. Invest. 97 (1996) 1732-1740
28. Di Gregorio G.B., Yamamoto M., Ali A.A., Abe E., Roberson P., Manolagas S.C., et al. Attenuation of the self-renewal of transit-amplifying osteoblast progenitors in the murine bone marrow by 17β-estradiol. J. Clin. Invest. 107 (2001) 803-812
29. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2 (1987) 595-610
30. Skinner R.A. Decalcification and paraffin processing techniques. In: An Y.H., and Martin K.L. (Eds). Handbook of histology methods for bone and cartilage (2003), Humana Press, Totowa, NJ 167-184
31. Fisher L.D., and van Belle G. Counting Data. Biostatistics: a methodology for the health sciences (1993), John Wiley and Sons, Inc., New York 176-245
32. Turner C.H., Owan I., Alvey T., Hulman J., and Hock J.M. Recruitment and proliferative responses of osteoblasts after mechanical loading in vivo determined using sustained-release bromodeoxyuridine. Bone 22 (1998) 463-469
33. Qin L., Li X., Ko J.K., and Partridge N.C. Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase. J. Biol. Chem. 280 (2005) 3104-3111
34. Borrelli E., Heyman R., Hsi M., and Evans R.M. Targeting of an inducible toxic phenotype in animal cells. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 7572-7576
35. Mesnil M., Piccoli C., Tiraby G., Willecke K., and Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. PNAS 93 (1996) 1831-1835
36. Visnjic D., Kalajzic I., Gronowicz G., Aguila H.L., Clark S.H., Lichtler A.C., et al. Conditional ablation of the osteoblast lineage in Col2.3Δtk transgenic mice. J. Bone Miner. Res. 16 (2001) 2222-2231
37. Parfitt A.M. Parathyroid hormone and periosteal bone expansion. J. Bone Miner. Res. 17 (2002) 1741-1743
38. Dobnig H., and Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136 (1995) 3632-3638
39. Nakajima A., Shimoji N., Shiomi K., Shimizu S., Moriya H., Einhorn T.A., et al. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J. Bone Miner. Res. 17 (2002) 2038-2047
40. Pettway G.J., Meganck J.A., Koh A.J., Keller E.T., Goldstein S.A., and McCauley L.K. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 42 (2008) 806-818
41. Krishnan V., Moore T.L., Ma Y.L., Helvering L.M., Frolik C.A., Valasek K.M., et al. PTH bone anabolic action requires Cbfa1/Runx2-dependent signaling. Mol. Endocrinol. 17 (2003) 423-435
42. Bikle D.D., Sakata T., Leary C., Elalieh H., Ginzinger D., Rosen C.J., et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J. Bone Miner. Res. 17 (2002) 1570-1578
43. Bellido T., Ali A.A., Gubrij I., Plotkin L.I., Fu Q., O'Brien C.A., et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146 (2005) 4577-4583
44. Keller H., and Kneissel M. SOST is a target gene for PTH in bone. Bone 37 (2005) 148-158
45. Niu Q., Warmington K.S., Grisanti M., Tan H., Ominsky M.S., Simonet W.S., et al. Sclerostin inhibition leads to increased periosteal and endocortical bone formation as well as decreased cortical porosity in aged ovariectomized rats. J. Bone Miner. Res. 22 (2007) S65